Sign Up
Stories
Spexis AG, NewAmsterdam Pharma, Molecure, and Cyclo Therapeutics: Key Updates
Share
Amgen to Lay Off Horizon Employees After...
Bavarian Nordic's Vaccine Transformation
Biotech Acquisitions & Layoffs
ANJESO Drug Insight and Market Forecast
Advancements in Cancer Treatment and Mar...
Advancements in Ovarian Cancer Detection...
Overview
API
Spexis AG announces changes to its Executive Committee, with Hernan Levett leaving as Chief Financial Officer. Martin Jakobovic will succeed him as interim Chief Financial Officer. NewAmsterdam Pharma appoints Ian Somaiya as Chief Financial Officer. Molecure provides first half 2023 financial results and updates on its clinical trials. Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. enter into a merger agreement.
Ask a question
How will the appointment of Ian Somaiya impact NewAmsterdam Pharma's financial strategy?
What are the implications of the changes in Spexis AG's Executive Committee?
What are the potential outcomes of the merger between Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc.?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Jun 2023
Jul 2023
Aug 2023
Sep 2023
Oct 2023
Coverage